股市必读：博瑞医药（688166）12月31日主力资金净流出1172.85万元，占总成交额6.32%

Core Viewpoint - The company, Borui Pharmaceutical, has announced a delay in the expected completion dates for several fundraising investment projects, pushing them to March 2027 due to regulatory approval processes and additional construction needs [2][3]. Trading Information Summary - On December 31, 2025, Borui Pharmaceutical's stock closed at 49.06 yuan, down 0.69%, with a turnover rate of 0.89% and a trading volume of 37,800 shares, amounting to a total transaction value of 186 million yuan [1]. - The net outflow of main funds was 11.73 million yuan, accounting for 6.32% of the total transaction value, while retail investors saw a net inflow of 5.07 million yuan, representing 2.73% of the total [2]. Company Announcement Summary - The Board of Directors approved a proposal to delay the expected completion dates for several fundraising investment projects to March 2027, which include the construction of an inhalation and chemical drug production base and a biopharmaceutical research center [2][3]. - The delay is attributed to products being in the approval stage and the need for additional construction of an automated warehouse, which requires synchronized acceptance [2][3]. - The delay does not change the intended use of the raised funds and does not affect the company's normal operations [2][3]. Internal Governance and Management Systems - The company has established an internal audit management system to ensure independent auditing of internal controls, financial information, and operational activities [4]. - A foreign exchange transaction management system has been implemented to mitigate exchange rate risks and ensure fund security, prohibiting speculative activities [5]. - The company has also set up a fundraising management method to regulate the use and supervision of raised funds, ensuring they are used exclusively for designated projects [6]. - A management system for shares held by directors and senior management has been created to regulate share transactions and disclosures [7].